drugset / Trial / NCT07479485
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2026-04
- Primary completion
- 2028-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Pucotenlimab | Monoclonal antibody | — | — |